Pfizer, the American pharmaceutical company, is nearing the completion of one of its largest deals in the pharmaceutical sector this year, as reports reveal that the giant company is in advanced talks to acquire the startup "Metsera," specializing in the development of obesity drugs, in a deal valued at approximately $3.7 billion. This move comes as part of Pfizer's efforts to strengthen its product line, especially after the failure of one of its weight loss drugs on which the company had highly relied.
According to the "Financial Times," the official announcement of the deal may happen on Monday, reflecting the rapid strategic moves Pfizer is making to face increasing competition in the global pharmaceuticals market. The newspaper clarified that Pfizer may pay around $47.50 per share of "Metsera," with an additional $22.50 if the startup meets certain agreed performance criteria.
"Metsera" represents a new generation of emerging companies trying to gain a foothold in the obesity drug market, a sector that is gaining momentum due to high demand and its value, estimated in billions of dollars. For Pfizer, acquiring "Metsera" means obtaining a promising drug, "MET-233i," which is an innovative injection that helped patients reduce up to 8.4% of their weight within just 36 days in a short-term clinical trial. This development enhances Pfizer's ability to enter the race with major pharmaceutical companies that are heavily investing in obesity treatments.
On the stock performance front, Pfizer shares (NYSE: PFE) rose 1.66% in pre-market trading, equivalent to $0.40, bringing the stock's trading near $24.43. This increase reflects investor confidence that the potential acquisition deal will strengthen Pfizer's position and open new horizons in a strategic sector that is growing in size and importance.
These developments confirm that Pfizer is moving forward with its strategy to expand its product portfolio, with a greater focus on areas that represent urgent global health needs, foremost of which is obesity treatment—a significant opportunity for long-term growth.
